Patent ID: 11884939
Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 4:
5. The engineered MVA strain of claim 1, wherein the MVA strain exhibits one or more of the following characteristics:
induction of increased levels of interferon beta (IFNB) expression in dendritic cells and THP-1 cells as compared to dendritic cells and THP-1 cells infected with the corresponding wild-type strain;
induction of increased levels of TBK1 and IRF3 phosphorylation in dendritic cells as compared to dendritic cells infected with the corresponding wild-type strain;
induction of increased levels of ISG expression in dendritic cells as compared to dendritic cells infected with the corresponding wild-type strain;
induction of increased levels of at least one of IFNB, CCL4, CCL5, CXCL10 in cancer cells as compared to cancer cells infected with the corresponding wild-type strain; and
reduction of tumor volume in tumors contacted with the engineered MVA strain as compared to tumors infected with the corresponding wild-type strain.